NCT06349317

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Name: Clinical Trial NCT06349317
Creator: Yongyi Zeng
Keywords: Hepatocellular Carcinoma, Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib, Phase 2, combination product, clinical trial

Neoadjuvant Intensity-modulated Radiotherapy Combined With Perioperative Camrelizumab and Apatinib in the Treatment of Resectable Hepatocellular Carcinoma Associated With Portal Vein Tumor Thrombus: a Single-arm Prospective Clinical Study

Yongyi Zeng·Phase 2·ClinicalTrials.gov·combination productNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatocellular Carcinoma
Drug/Device/Intervention: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
Study type: Interventional
Intervention type: combination product

Sponsor & location

Primary sponsor: Yongyi Zeng
Funder: Meng Chao Hepatobiliary Hospital of Fujian Medical University

Timeline & enrollment

Phase: Phase 2
Start date: May 01, 2024
End date: Jun 01, 2026
Enrollment: 33 participants

Primary outcome

1-year Event-Free Survival (EFS) rate

Summary

This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus.

ICD-10 classifications

Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06349317
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06349317 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yongyi Zeng and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.